Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLaCE: 4-Factor PCC in Traumatic Coagulopathy
NCT03981484Phase 2Unknown
- Start
- Jan 2020
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised trial in trauma-induced coagulopathy (TIC) and hemorrhage comparing PCC + Standard of Care with Standard of Care (2 arms). Primary endpoints: 24 Hour Mortality and 30 Day Mortality. Status: unknown.
02
Drugs
prothrombin complex concentrate, human
03
Conditions
trauma-induced coagulopathy (TIC)hemorrhage
Beyond the preview
Go deeper on NCT03981484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981484.